Moderna Expects $1.9 Billion in Sales for 2025

Moderna said recently that it expects to report about $1.9 billion in sales for 2025, near the upper end of its previously projected $1.6 billion to $2 billion range but well below revenue levels seen during the COVID-19 pandemic, Patrick Wingrove reported for Reuters.

The decline of US vaccination rates, at the lower end of the company’s projected 20% to 40% drop, ultimately resulted in higher sales. (Photo: Moderna)

Chief Financial Officer James Mock said in an interview that US vaccination rates in the retail sector fell by roughly 26% year over year in 2025. That decline, at the lower end of the company’s projected 20% to 40% drop, ultimately resulted in higher sales, he said.

The vaccine maker, which is set to present at the JPMorgan Healthcare Conference in San Francisco, also cut $200 million from its 2025 operating-expense forecast, lowering the range to $5.0 billion to $5.2 billion.

Moderna said it expects to end the year with $8.1 billion in cash, up from its prior forecast of $6.5 billion to $7.0 billion.